2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172277A
    DSPE-PEG2000-R9 98%
    DSPE-PEG2000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG2000-R9 can be used for drug delivery.
    DSPE-PEG2000-R9
  • HY-172277B
    DSPE-PEG5000-R9 98%
    DSPE-PEG5000-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG5000-R9 can be used for drug delivery.
    DSPE-PEG5000-R9
  • HY-172277C
    DSPE-PEG3400-R9
    DSPE-PEG3400-R9 is a PEG compound which composed of DSPE and a poly-arginine-9 peptide (R9). DSPE-PEG3400-R9 can be used for drug delivery.
    DSPE-PEG3400-R9
  • HY-172708A
    DSPE-PEG3400-PP1
    DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery.
    DSPE-PEG3400-PP1
  • HY-173251S
    ENX-101 98%
    ENX-101 is an orally active (GABAA) receptor partial positive allosteric modulator (PAM). ENX-101 is selective to α2β2γ2L (EC50 = 0.76 nM), α2β3γ2L (EC50 = 0.61 nM), α3 (EC50 = 1.97 nM), α5 (EC50 = 0.85 nM) subunits of GABA receptor. ENX-101 possesses antiseizure activity in several animal models.
    ENX-101
  • HY-17355AR
    Dexpramipexole dihydrochloride (Standard) 104632-27-1
    Dexpramipexole (dihydrochloride) (Standard) is the analytical standard of Dexpramipexole (dihydrochloride). This product is intended for research and analytical applications. Dexpramipexole dihydrochloride ((R)-Pramipexole dihydrochloride) is a neuroprotective agent and weak non-ergoline dopamine agonist.
    Dexpramipexole dihydrochloride (Standard)
  • HY-17355S1
    Pramipexole-d5 dihydrochloride 1217601-58-5 98%
    Pramipexole-d5 dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole-d5 dihydrochloride
  • HY-17355S2
    Pramipexole-d7-1 dihydrochloride 2702798-58-9 98%
    Pramipexole-d7-1 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS).
    Pramipexole-d7-1 dihydrochloride
  • HY-17360S1
    Tiotropium-d6 bromide 1126775-44-7 98%
    Tiotropium-d6 (bromide) is deuterium labeled Tiotropium (Bromide). Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.
    Tiotropium-d6 bromide
  • HY-17366AR
    Clozapine N-oxide dihydrochloride (Standard) 2250025-93-3
    Clozapine N-oxide (dihydrochloride) (Standard) is the analytical standard of Clozapine N-oxide (dihydrochloride). This product is intended for research and analytical applications. Clozapine N-oxide dihydrochloride is a major metabolite of Clozapine and a human muscarinic designer receptors (DREADDs) agonist. Clozapine N-oxide dihydrochloride activates the DREADD receptor hM3Dq and hM4Di. Clozapine N-oxide dihydrochloride can cross the blood-brain barrier[1][2][3][4]. Clozapine is a potent dopamine antagonist and also a potent and selective muscarinic M4 receptor (EC50=11 nM) agonist[5][6].
    Clozapine N-oxide dihydrochloride (Standard)
  • HY-17368S2
    Rivastigmine-d3 hydrochloride 98%
    Rivastigmine-d3 hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
    Rivastigmine-d3 hydrochloride
  • HY-17387S1
    (-)-Huperzine A-d4 hydrochloride 98%
    (-)-Huperzine A-d4 hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease.
    (-)-Huperzine A-d4 hydrochloride
  • HY-17410S1
    Iloperidone-d3 hydrochloride 98%
    Iloperidone-d3 hydrochloride is deuterated labeled Iloperidone (HY-17410). Iloperidone (HP 873) is a D2/5-HT2 receptor antagonist. Iloperidone is an atypical antipsychotic for the schizophrenia symptoms.
    Iloperidone-d3 hydrochloride
  • HY-17412AS
    Minocycline-d6 1036070-10-6 98%
    Minocycline-d6 is deuterium labeled Minocycline (HY-17412A). Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
    Minocycline-d6
  • HY-17416AS
    Guanfacine-13C,15N3 1189924-28-4 98%
    Guanfacine-13C,15N3 is the 13C and 15N labeled Guanfacine. Guanfacine is an orally active noradrenergic α2A agonist and has high selective for the α2A receptor subtype. Guanfacine has effects in producing hypotension and sedation. Guanfacine can be used for the research of a variety of prefrontal cortex (PFC) cognitive disorders, including tourette's syndrome and attention deficit hyperactivity disorder (ADHD).
    Guanfacine-13C,15N3
  • HY-17417AR
    Naloxone (Standard) 465-65-6
    Naloxone (Standard) is the analytical standard of Naloxone. This product is intended for research and analytical applications. Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias.
    Naloxone (Standard)
  • HY-17447AS
    (1S,2R)-Tranylcypromine-d5 hydrochloride 98%
    (1S,2R)-Tranylcypromine-d5 (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression.
    (1S,2R)-Tranylcypromine-d5 hydrochloride
  • HY-17447SA
    Tranylcypromine-d5 hydrochloride 107077-98-5 98%
    Tranylcypromine-d5 (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis.
    Tranylcypromine-d5 hydrochloride
  • HY-17611A1
    Etripamil hydrochloride 2560549-35-9 98%
    Etripamil (MSP-2017) hydrochloride is a short-acting, L-type calcium channel antagonist that can be used in the study of paroxysmal supraventricular tachycardia (PSVT). Etripamil hydrochloride inhibits calcium influx through slow calcium channels, thereby slowing atrioventricular node conduction and prolonging the atrioventricular node refractory period.
    Etripamil hydrochloride
  • HY-176436S
    GW-117 2260629-83-0 98%
    GW-117 is a 5-HT2C receptor antagonist and a melatonin (MT1/MT2) receptor agonist. GW-117 shows antidepressant-like and anxiolytic-like effects.
    GW-117
Cat. No. Product Name / Synonyms Application Reactivity